Source link : https://www.newshealth.biz/health-news/fda-rejects-mdma-at-for-ptsd-but-lykos-vows-to-push-on/
The US Food and Drug Administration’s (FDA) decision not to approve midomafetamine-assisted therapy (MDMA-AT) for posttraumatic stress disorder (PTSD) puts the therapy’s near-term future in doubt, but officials say the rejection may not knock it out of contention as an eventual therapeutic tool for a variety of conditions. As reported by Medscape Medical News, earlier […]
Author : News Health
Publish date : 2024-09-02 06:05:28
Copyright for syndicated content belongs to the linked Source.
inHealth